Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate receptor ionotropic, kainate 3 (GRIK3, also known as GluK3 or GluR7) is a ligand-gated ion channel that belongs to the kainate subfamily of ionotropic glutamate receptors. It functions as a cation-permeable channel activated by the binding of L-glutamate and kainic acid, converting chemical signals into electrical impulses at excitatory synapses in the central nervous system. GRIK3 is widely expressed in the brain, particularly in the neocortex and dentate gyrus of the hippocampus, where it plays a critical role in synaptic transmission, presynaptic facilitation, and synaptic plasticity.
Dysregulation or genetic polymorphisms of GRIK3, such as the Ser310Ala variant, have been linked to various neuropsychiatric and neurodegenerative disorders, including schizophrenia, major depressive disorder, epilepsy, and alcohol dependence. Additionally, aberrant overexpression of GRIK3 has been implicated in several malignancies, such as breast and colorectal cancers, where it promotes cell proliferation, migration, and epithelial-mesenchymal transition. Pharmacological targeting of GRIK3 involves agonists like glutamic acid and kainic acid, antagonists like UBP310 and quinoxalinedione derivatives, and positive allosteric modulators like BPAM344, making it an attractive therapeutic target for both neurological conditions and oncology.
Drugs targeting GRIK3 act primarily as agonists, antagonists, or allosteric modulators. Agonists like glutamic acid and kainic acid bind to the ligand-binding domain, inducing a conformational change that opens the cation channel to allow sodium and calcium influx. Antagonists, such as UBP310 or quinoxalinedione derivatives, competitively block agonist binding to inhibit channel activation. Positive allosteric modulators, such as BPAM344, bind to the dimer interface of the ligand-binding domain, stabilizing it to slow desensitization and potentiate receptor currents.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, kainate 3 (GRIK3).